Video

Dr. Gertz on Expanding Treatment Options for Myeloma

Author(s):

Morie Gertz, MD

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

There are a number of new agents that are being used for the management of myeloma, says Gertz. Daratumumab, a fully human IgG1k monoclonal antibody that targets CD38, has demonstrated promising activity as monotherapy in patients with relapsed/refractory multiple myeloma.

Carfilzomib, lenalidomide, and dexamethasone have been shown to improve progression-free survival. Panobinostat, a deacetylase (DAC) inhibitor is also being used in new ways to treat myeloma.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Image Credit: ©Dr_Microbe - stock.adobe.com
July 19th 2024

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Noa Biran, MD
July 9th 2024

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

Ying Huang, PhD
July 2nd 2024

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy